Table 2 Antihypertensive (AH) medications use and risk of ovarian cancer, all-cause and non-cancer mortality
AH medica-tion use | Ovarian cancer mortality | All-cause mortality | Non-cancer mortality | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Deaths/ Cases, n | HR (95% CI) | Deaths/ Cases, n | HR (95% CI) | Deaths/ Cases, n | HR (95% CI) | ||||||
Age-adjusted | Fully adjusteda | Age-adjusted | Fully adjusteda | Age-adjusted | Fully adjusteda | ||||||
SNS-AH | |||||||||||
Non-use | 219/537 | 1.00 | 1.00 | 248/537 | 1.00 | 1.00 | 15/537 | 1.00 | 1.00 | ||
Use | 23/51 | 0.96 (0.61; 1.50) | 1.05 (0.61; 1.80) | 31/51 | 1.08 (0.73; 1.59) | 1.12 (0.71; 1.79) | 5/51 | 1.97 (0.69; 5.67) | 1.46 (0.41; 5.11) | ||
lowb | 10/25 | 0.91 (0.48; 1.73) | 1.01 (0.48; 2.10) | 15/25 | 1.17 (0.68; 1.99) | 1.19 (0.64; 2.19) | |||||
high | 13/26 | 1.00 (0.56; 1.79) | 1.08 (0.56; 2.11) | 16/26 | 1.00 (0.59; 1.69) | 1.07 (0.59; 1.93) | |||||
Diuretics | |||||||||||
Non-use | 190/471 | 1.00 | 1.00 | 213/471 | 1.00 | 1.00 | 13/471 | 1.00 | 1.00 | ||
Use | 52/117 | 0.84 (0.60; 1.17) | 1.03 (0.68; 1.56) | 66/117 | 0.90 (0.67; 1.21) | 0.97 (0.67; 1.41) | 7/117 | 1.03 (0.39; 2.74) | 0.57 (0.16; 1.98) | ||
lowb | 28/58 | 0.88 (0.57; 1.34) | 0.99 (0.61; 1.62) | 34/58 | 0.89 (0.60; 1.31) | 0.90 (0.58; 1.41) | |||||
high | 24/59 | 0.80 (0.52; 1.24) | 1.09 (0.64; 1.87) | 32/59 | 0.91 (0.61; 1.33) | 1.07 (0.67; 1.73) | |||||
Beta blockers | |||||||||||
Non-use | 165/422 | 1.00 | 1.00 | 187/422 | 1.00 | 1.00 | 11/422 | 1.00 | 1.00 | ||
Use | 77/166 | 1.10 (0.83; 1.46) | 1.43 (0.98; 2.08) | 92/166 | 1.11 (0.85; 1.44) | 1.32 (0.94; 1.86) | 9/166 | 1.34 (0.54; 3.33) | 0.89 (0.29; 2.73) | ||
lowb | 44/82 | 1.37 (0.97; 1.93) | 1.67 (1.10; 2.53) | 50/82 | 1.31 (0.95; 1.81) | 1.50 (1.02; 2.21) | |||||
high | 33/84 | 0.87 (0.60; 1.28) | 1.12 (0.69; 1.83) | 42/84 | 0.94 (0.67; 1.32) | 1.10 (0.71; 1.71) | |||||
Calcium channel blockers | |||||||||||
Non-use | 216/515 | 1.00 | 1.00 | 240/515 | 1.00 | 1.00 | 13/515 | 1.00 | 1.00 | ||
Use | 26/73 | 0.66 (0.43; 1.00) | 0.75 (0.45; 1.23) | 39/73 | 0.85 (0.60; 1.23) | 0.95 (0.62; 1.45) | 7/73 | 2.21 (0.83; 5.88) | 1.75 (0.53; 5.72) | ||
lowb | 10/34 | 0.57 (0.30; 1.08) | 0.84 (0.41; 1.73) | 16/34 | 0.80 (0.48; 1.33) | 1.05 (0.58; 1.90) | |||||
high | 16/39 | 0.73 (0.43; 1.24) | 0.70 (0.39; 1.26) | 23/39 | 0.90 (0.58; 1.41) | 0.89 (0.54; 1.48) | |||||
Angiotensin receptor blockers | |||||||||||
Non-use | 218/526 | 1.00 | 1.00 | 245/526 | 1.00 | 1.00 | 13/526 | 1.00 | 1.00 | ||
Use | 24/62 | 0.81 (0.52; 1.24) | 0.73 (0.43; 1.23) | 34/62 | 0.99 (0.68; 1.43) | 0.89 (0.57; 1.39) | 7/62 | 3.07 (1.17; 8.06) | 2.45 (0.72; 8.31) | ||
lowb | 12/31 | 0.87 (0.48; 1.57) | 0.64 (0.31; 1.30) | 18/31 | 1.12 (0.69; 1.83) | 0.90 (0.50; 1.62) | |||||
high | 12/31 | 0.75 (0.42; 1.36) | 0.82 (0.43; 1.57) | 16/31 | 0.87 (0.52; 1.45) | 0.88 (0.49; 1.56) | |||||
ACE inhibitors | |||||||||||
Non-use | 187/443 | 1.00 | 1.00 | 212/443 | 1.00 | 1.00 | 14/443 | 1.00 | 1.00 | ||
Use | 55/145 | 0.68 (0.50; 0.94) | 0.55 (0.36; 0.83) | 67/145 | 0.70 (0.52; 0.93) | 0.55 (0.38; 0.80) | 6/145 | 0.67 (0.25; 1.81) | 0.56 (0.17; 1.84) | ||
lowb | 27/72 | 0.69 (0.45; 1.05) | 0.65 (0.40; 1.05) | 33/72 | 0.66 (0.46; 0.94) | 0.63 (0.41; 0.97) | |||||
high | 28/73 | 0.68 (0.45; 1.02) | 0.46 (0.28; 0.77) * | 34/73 | 0.76 (0.51; 1.13)* | 0.48 (0.30; 0.76) * | |||||